Disease Awareness Remains Key Limitation in Hyperhidrosis Market

A report from GlobalData reports that the main barrier to growth in the United States axillary hyperhidrosis market is limited disease awareness.

While the axillary hyperhidrosis (AH) market in the United Stateshas grown at a compound annual growth rate (CAGR) of 15.7%—from $65.6 million in 2020 to $281.8 million by 2030—it isstill being limited. The main barrier to further growth is lack ofawareness for the disease. Additionally, unmet needs will not be addressed during the forecast period, according to GlobalData.

According to GlobalData’s latest report, the growth in this market will be driven by sales of high-priced neuromuscular blockades. However, a main barrier to growth is low diagnosis rates caused by limited disease awareness and this will continue to keep the diagnosis and treatment cases at a low rate, the article explained, noting that the way awareness would solve this is by making teaching patients and doctors about these issues and creating more opportunities for treatment.

“A large number of symptomatic treatments are currently being used off-label due to strict health insurance coverage criteria for marketed drugs,” said MandanaEmamzadeh, PhD, healthcare analyst at GlobalData.“The most frequently used drug classes are antiperspirants, anticholinergics, and neuromuscular blockades.”

There are 2 FDA approved treatments highlighted in the report for the symptomatic management of AH: glycopyrronium tosylate (Qbrexza; Journey Medical Corporation) and onabotulinumtoxin A (Botox; Allergan), which is predicted to stay as the leading treatment with a projected $111.8 million in sales in 2030.

“The greatest unmet needs within the AH market are improved anticholinergic drug delivery systems, therapies causing longer-lasting neuromuscular blockade, increased awareness and education, and better insurance coverage for treatments,” said Emamzadeh.“ Further, [sofpironium bromide](Ecclock; Brickell Biotech), a me-too drug and a reformulation of anticholinergics, is the only pipeline agent in phase 3 development.”

With the lack of pipeline movement and innovation, GlobalData expects the unmet needs will not be addressed during 2020-2030, and opportunity remains for developers in the AH market.

Visit Dermatology Times®for additional coverage on AH.

Reference:

Limited disease awareness will remain the main barrier to growth in the US axillary hyperhidrosis market, says GlobalData. GlobalData. Published January 24, 2022. Accessed February 11, 2022. https://www.globaldata.com/limited-disease-awareness-will-remain-main-barrier-growth-us-axillary-hyperhidrosis-market-says-globaldata/